---
layout: default
title: Naproxen
description: "Naproxen çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 111
evidence_level: L5
indication_count: 4
---

# Naproxen

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Naproxenï¼šå¾ æ¶ˆç‚é®ç—› åˆ° ç½•è¦‹éª¨éª¼ç™¼è‚²ç—‡å€™ç¾¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Naproxen å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Naproxenï¼ˆé‚£æ™®æ´›è¾›ï¼‰æ˜¯ä¸€ç¨®éé¡å›ºé†‡æŠ—ç™¼ç‚è—¥ç‰©ï¼ˆNSAIDï¼‰ï¼Œå»£æ³›ç”¨æ–¼æ²»ç™‚é—œç¯€ç‚ã€ç–¼ç—›å’Œç™¼ç‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°æ•¸ç¨®ç½•è¦‹éª¨éª¼ç™¼è‚²ç•°å¸¸ç–¾ç—…æœ‰æ½›åœ¨é—œè¯ï¼ŒåŒ…æ‹¬ **brachydactyly-syndactyly syndrome**ï¼Œä½†ç„¡ä»»ä½•è‡¨åºŠæˆ–æ–‡ç»è­‰æ“šæ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éª¨é—œç¯€ç‚ã€é¡é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—›é¢¨ã€åŸç™¼æ€§ç¶“ç—›ã€è¼•ä¸­åº¦ç–¼ç—› |
| é æ¸¬æ–°é©æ‡‰ç—‡ | osteoarthritis susceptibilityã€rheumatoid arthritisã€brachydactyly-syndactyly syndromeã€osteoarthritis |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.35% (brachydactyly-syndactyly syndrome) |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 167 å¼µ |
| å»ºè­°æ±ºç­– | Hold |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬ä¸åˆç†ï¼Ÿ

Naproxen é€šéæŠ‘åˆ¶ç’°æ°§åŒ–é…¶ï¼ˆCOX-1 å’Œ COX-2ï¼‰æ¸›å°‘å‰åˆ—è…ºç´ åˆæˆï¼Œç™¼æ®æŠ—ç™¼ç‚ã€é®ç—›å’Œè§£ç†±ä½œç”¨ã€‚

**é æ¸¬é©æ‡‰ç—‡å•é¡Œï¼š**
- Brachydactyly-syndactyly syndrome ç­‰æ˜¯å…ˆå¤©æ€§éª¨éª¼ç™¼è‚²ç•°å¸¸
- é€™äº›ç–¾ç—…ç‚ºéºå‚³æ€§ç–¾ç—…ï¼Œéç™¼ç‚ä»‹å°
- NSAID é¡è—¥ç‰©ç„¡æ³•æ”¹è®Šéª¨éª¼ç™¼è‚²çš„éºå‚³åŸºç¤
- ç¼ºä¹ä»»ä½•è—¥ç†å­¸æ©Ÿè½‰æ”¯æŒ

æ­¤é æ¸¬æ¥µå¯èƒ½æ˜¯ TxGNN æ¨¡å‹çš„å½é™½æ€§çµæœï¼Œå¯èƒ½æºæ–¼çŸ¥è­˜åœ–è­œä¸­éª¨éª¼ç›¸é—œè¡“èªçš„å…±ç¾ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

## æ–‡ç»è­‰æ“š

ç„¡ç›¸é—œæ–‡ç»ã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028724è™Ÿ | é‚£æ™®æ´›è¾› | åŸæ–™è—¥ | æ¶ˆç‚é®ç—›åŠ‘ |
| è¡›ç½²è—¥è£½å­—ç¬¬019620è™Ÿ | é‚£æ™®æ´›å…ˆéŒ  | éŒ åŠ‘ | é¢¨æ¿•é—œç¯€ç‚ã€è„Šæ¤ç‚ã€è…±é˜ç‚ä¹‹æ¶ˆç‚é®ç—› |
| è¡›ç½²è—¥è£½å­—ç¬¬034014è™Ÿ | è¡›é”æ‹¿ç‚éŒ 375æ¯«å…‹ | éŒ åŠ‘ | éª¨é—œç¯€ç‚ã€é¡é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—›é¢¨ã€åŸç™¼æ€§ç¶“ç—› |

## å®‰å…¨æ€§è€ƒé‡

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆä¸­åº¦ï¼‰ï¼š**
- Famotidine, Ranitidineï¼šH2 é˜»æ–·åŠ‘å¯èƒ½èˆ‡ NSAID äº¤äº’ä½œç”¨
- Metforminï¼šå¯èƒ½å¢åŠ ä¹³é…¸é…¸ä¸­æ¯’é¢¨éšª
- Aspirinï¼šå¢åŠ èƒƒè…¸é“å‡ºè¡€é¢¨éšª
- Corticosteroidsï¼ˆHydrocortisone, Dexamethasone, Betamethasone ç­‰ï¼‰ï¼šå¢åŠ èƒƒè…¸é“æ½°ç˜å’Œå‡ºè¡€é¢¨éšª
- Esomeprazole, Lansoprazoleï¼šèƒƒé…¸æŠ‘åˆ¶åŠ‘

**ä¸»è¦è­¦å‘Šï¼š**
- å¿ƒè¡€ç®¡äº‹ä»¶é¢¨éšªï¼ˆå¿ƒè‚Œæ¢—å¡ã€ä¸­é¢¨ï¼‰
- èƒƒè…¸é“å‡ºè¡€å’Œæ½°ç˜
- è…åŠŸèƒ½æå®³
- éæ•åæ‡‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as...
- å»ºè­°ï¼šPatients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¡ Moderate
- Anaprox and Anaprox DS (brands of naproxen sodium) contain 25 mg and 50 mg of sodium per tablet (approximately 1 mEq/250 mg naproxen), respectively, and Naprosyn suspension contains 39 mg per teaspoonful (approximately 1.5 mEq/125 mg naproxen).  The ...

**Anemia** ğŸŸ¡ Moderate
- Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be ...

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¡ Moderate
- Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are exp...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevati...

**Hyperkalemia** ğŸŸ¡ Moderate
- Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects h...

*å¦æœ‰ 8 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
TxGNN é æ¸¬çš„é©æ‡‰ç—‡ï¼ˆçŸ­æŒ‡ä½µæŒ‡ç—‡å€™ç¾¤ç­‰ï¼‰æ˜¯ç½•è¦‹çš„å…ˆå¤©æ€§éºå‚³ç–¾ç—…ï¼Œèˆ‡ NSAID çš„æŠ—ç™¼ç‚æ©Ÿè½‰å®Œå…¨ç„¡é—œã€‚é€™äº›éª¨éª¼ç™¼è‚²ç•°å¸¸æ˜¯åœ¨èƒšèƒç™¼è‚²æœŸå½¢æˆçš„çµæ§‹ç¼ºé™·ï¼Œéç™¼ç‚éç¨‹æ‰€è‡´ï¼Œå› æ­¤ naproxen ä¸å¯èƒ½å°å…¶æœ‰æ²»ç™‚æ•ˆæœã€‚æ­¤é æ¸¬æ‡‰è¦–ç‚ºæ¨¡å‹çš„å½é™½æ€§çµæœã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ä¸å»ºè­°é€²ä¸€æ­¥æ¢ç´¢
- æ­¤é æ¸¬ç¼ºä¹ä»»ä½•ç§‘å­¸ä¾æ“š


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Dehydrocholic Acid]({{ "/drugs/dehydrocholic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pentoxifylline]({{ "/drugs/pentoxifylline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bevacizumab]({{ "/drugs/bevacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Naproxenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/naproxen/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_naproxen,
  title = {Naproxenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/naproxen/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
